What is Zacks Research’s Estimate for RVPH FY2026 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities research analysts at Zacks Research reduced their FY2026 earnings per share estimates for shares of Reviva Pharmaceuticals in a report issued on Wednesday, April 1st. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings of ($2.21) per share for the year, down from their previous estimate of ($2.20). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ FY2027 earnings at ($1.74) EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 target price on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Wall Street Zen upgraded Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, March 14th. Finally, D. Boral Capital downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $66.67.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH opened at $0.72 on Friday. The stock has a market cap of $4.64 million, a price-to-earnings ratio of -0.08 and a beta of 0.64. The business has a 50 day simple moving average of $3.78 and a 200 day simple moving average of $7.68. Reviva Pharmaceuticals has a 52-week low of $0.59 and a 52-week high of $23.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd raised its holdings in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares during the period. State Street Corp grew its holdings in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares during the period. Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals by 87.6% during the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after purchasing an additional 489,711 shares during the period. Millennium Management LLC increased its position in Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the last quarter. Finally, Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the third quarter valued at approximately $37,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.